{"id":5,"date":"2023-11-28T09:10:51","date_gmt":"2023-11-28T09:10:51","guid":{"rendered":"http:\/\/gebro.es\/?page_id=5"},"modified":"2024-03-07T09:56:38","modified_gmt":"2024-03-07T09:56:38","slug":"home","status":"publish","type":"page","link":"https:\/\/gebro.es\/en\/","title":{"rendered":"Home"},"content":{"rendered":"
\n
\n \"\"\n <\/div>\n
\n
\n
\n

We care about life,\u2028we improve your health.<\/h1>\n <\/div>\n <\/div>\n <\/div>\n<\/section>\n\n\n
\n

About Gebro<\/h2>\n
\n

At Gebro Pharma we strive day by day to improve people\u2019s health and quality of life by combining science, innovation and talent.<\/p>\n\n \n

\n \n\n<\/svg>\n<\/div>\n Discover more about the company\n <\/a>\n <\/div>\n
\n
\n

History<\/h3>\n \n
\n \n\n<\/svg>\n<\/div>\n <\/a>\n
\n \"\"\n <\/div>\n <\/div>\n
\n

Transparency and Ethics<\/h3>\n \n
\n \n\n<\/svg>\n<\/div>\n <\/a>\n
\n \"\"\n <\/div>\n <\/div>\n <\/div>\n <\/section>\n\n\n
\n
\n
\n

\n Business development \/Innovation\n <\/h2>\n
\n

We actively pursue synergies to boost innovation, forging collaborative and licensing agreements with other companies in the pharmaceutical and biotechnology fields.<\/p>\n\n \n

\n \n\n<\/svg>\n<\/div>\n Learn more\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n \n \"\"\n <\/div>\n <\/section>\n\n\n\n
\n
\n
\n

\n Science and research\n <\/h2>\n
\n

At Gebro Pharma we are committed to a dynamic research strategy through which we establish synergies with prestigious scientific partners to create innovative solutions in our therapeutic areas.<\/p>\n\n \n

\n \n\n<\/svg>\n<\/div>\n Explore further\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n \n \"\"\n <\/div>\n <\/section>\n\n\n\n
\n

Therapeutic areas<\/h2>\n
\n
\n

Our pharmaceutical company is a benchmark in the fields of pain, respiratory, autoimmune diseases, and urogynecology, developing new solutions and products to enhance patients’ quality of life.<\/p>\n\n \n

\n \n\n<\/svg>\n<\/div>\n Read more\n <\/a>\n <\/div>\n <\/div>\n
\n \n \n\n\n\n<\/svg>\n

Autoimmune Diseases Area<\/h3>\n <\/a>\n \n \n\n\n\n<\/svg>\n

Pain Area<\/h3>\n <\/a>\n \n \n\n\n\n<\/svg>\n

Respiratory Area<\/h3>\n <\/a>\n \n \n\n\n\n<\/svg>\n

Urology and Gynecology Area<\/h3>\n <\/a>\n \n \n\n\n\n<\/svg>\n

Hospital Area<\/h3>\n <\/a>\n <\/div>\n<\/section>\n\n\n
\n \n \n \"\"\n <\/picture>\n
\n
\n
\n

Products<\/h2>\n
\n

Explore our portfolio of drugs, medicines and healthcare products.<\/p>\n\n \n

\n \n\n<\/svg>\n<\/div>\n View all products\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/section>\n\n\n
\n
\n
\n

Other resources<\/p>\n <\/div>\n

\n\n \"\"\n\n
\n
\n

\n \"\"\n Gebro Health Talks\n <\/h2>\n
\n

Our will is to share knowledge and talk with the scientific community. Find out more about our training sessions.<\/p>\n\n \n

\n \n\n<\/svg>\n<\/div>\n Read more\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n
\n

\n \"\"\n Gebro Health Talks\n <\/h3>\n \n
\n \n\n<\/svg>\n<\/div>\n <\/a>\n \n <\/div>\n\n <\/div>\n
\n\n \"\"\n\n
\n
\n

\n \"\"\n Tu salud\n <\/h2>\n
\n

El espacio para pacientes con problemas de asma.<\/p>\n\n \n

\n \n\n<\/svg>\n<\/div>\n Read more\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n
\n

\n \"\"\n Tu salud\n <\/h3>\n \n
\n \n\n<\/svg>\n<\/div>\n <\/a>\n \n <\/div>\n\n <\/div>\n \n <\/div>\n<\/section>\n\n\n
\n

Pathologies<\/h2>\n
\n
\n

Find in-depth information about the pathologies related to our therapeutic areas.<\/p>\n\n \n

\n \n\n<\/svg>\n<\/div>\n Learn more\n <\/a>\n <\/div>\n <\/div>\n
\n \n \n\n\n\n<\/svg>\n

Rheumatoid Arthritis<\/h3>\n <\/a>\n \n \n\n\n\n<\/svg>\n

Asthma<\/h3>\n <\/a>\n \n \n\n\n\n<\/svg>\n

COPD<\/h3>\n <\/a>\n \n \n\n\n\n<\/svg>\n

Overactive bladder<\/h3>\n <\/a>\n \n \n\n\n\n<\/svg>\n

Bladder Cancer<\/h3>\n <\/a>\n \n \n\n\n\n<\/svg>\n

Chronic Pain<\/h3>\n <\/a>\n <\/div>\n<\/section>\n\n\n
\n \n \n \"\"\n <\/picture>\n
\n
\n
\n

Gebro talent<\/h2>\n
\n

Certified as a Great Place to Work company, at Gebro Pharma we promote a healthy environment where people can develop their full personal and professional potential.<\/p>\n\n \n

\n \n\n<\/svg>\n<\/div>\n Our people, our DNA\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/section>\n\n\n
\n

Gebro
economic figures<\/h2>\n
\n
\n
\n 150\n <\/div>\n
\n 94M\u20ac\n <\/div>\n
\n 3M\u20ac\n <\/div>\n <\/div>\n\n <\/div>\n
\n
\n
Employees<\/div>\n
Net Sales<\/div>\n
Investment 2022<\/div>\n <\/div>\n<\/section>\n\n\n
\n

News<\/h2>\n
\n
\n

Stay up to date with the latest news from Gebro Pharma.<\/p>\n<\/div>

\n
\n \n
\n \n\n<\/svg>\n<\/div>\n See all news\n <\/a>\n <\/div>\n
\n
\n
\n \n\n<\/svg>\n<\/div>\n <\/div>\n
\n
\n \n\n<\/svg>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n \n
\n \n
\n
\n
\n \n \"\"\n <\/a>\n
\n
\n
\n Press<\/a>\n January 19, 2024<\/span>\n <\/div>\n \n

Sergi Aulinas (Gebro Pharma): \u201cHay que actuar en el precio de los f\u00e1rmacos regulados esenciales para que sean rentables\u201d<\/h3>\n <\/a>\n <\/div>\n \n

El pasado mes de enero Sergi Aulinas, CEO de Gebro Pharma, realiz\u00f3 una entrevista con el peri\u00f3dico econ\u00f3mico Cinco D\u00edas. En ella cuenta un reciente relanzamiento de un producto de la compa\u00f1\u00eda, hecho posible gracias a un acuerdo coinversiones. Aulinas se\u00f1ala los desaf\u00edos en el acceso a nuevos medicamentos y aboga por una sanidad p\u00fablica […]<\/p>\n \n

\n \n\n<\/svg>\n<\/div>\n Read more\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n
\n
\n \n \"\"\n <\/a>\n
\n
\n
\n Corporate<\/a>\n June 09, 2023<\/span>\n <\/div>\n \n

BIT Pharma’s Nicaplant\u00ae implants, licensed in Spain by Laboratorios Gebro Pharma, achieve the EMA’s PRIME designation<\/h3>\n <\/a>\n <\/div>\n \n

Laboratorios Gebro Pharma, S.A. and BIT Pharma signed an agreement back in 2022 for the commercialization of Nicaplant\u00ae in Spain, subject to prior regulatory approval. The implants, currently in development, are intended to prevent cerebral vasospasm, a severe complication that occurs in a high percentage of patients who have suffered a subarachnoid hemorrhage. This type […]<\/p>\n \n

\n \n\n<\/svg>\n<\/div>\n Read more\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n <\/div>\n\n <\/div>\n <\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-5","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nGebro Pharma<\/title>\n\n\n\n\n\n\n\n\n\n\n\n\n\t\n